Fundamental Analysis of NEURONETICS INC(NASDAQ:STIM) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to STIM. STIM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of STIM have multiple concerns. While showing a medium growth rate, STIM is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year STIM has reported negative net income.

STIM had a negative operating cash flow in the past year.

STIM had negative earnings in each of the past 5 years.

In the past 5 years STIM always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of STIM (-49.14%) is worse than 66.84% of its industry peers.

Looking at the Return On Equity, with a value of -388.26%, STIM is doing worse than 86.10% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-49.14%
ROE	-388.26%
ROIC	N/A

ROA(3y)-26.65%

ROA(5y)-28.76%

ROE(3y)-63.33%

ROE(5y)-71.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

STIM's Gross Margin of 75.70% is amongst the best of the industry. STIM outperforms 87.17% of its industry peers.

In the last couple of years the Gross Margin of STIM has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for STIM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	75.7%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.81%

GM growth 5Y-1.05%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, STIM has more shares outstanding

Compared to 5 years ago, STIM has more shares outstanding

Compared to 1 year ago, STIM has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -7.11, we must say that STIM is in the distress zone and has some risk of bankruptcy.

STIM's Altman-Z score of -7.11 is on the low side compared to the rest of the industry. STIM is outperformed by 72.73% of its industry peers.

A Debt/Equity ratio of 4.90 is on the high side and indicates that STIM has dependencies on debt financing.

STIM's Debt to Equity ratio of 4.90 is on the low side compared to the rest of the industry. STIM is outperformed by 89.30% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	4.9
Debt/FCF	N/A
Altman-Z	-7.11

ROIC/WACCN/A

WACC10.53%

2.3 Liquidity

A Current Ratio of 3.16 indicates that STIM has no problem at all paying its short term obligations.

The Current ratio of STIM (3.16) is comparable to the rest of the industry.

STIM has a Quick Ratio of 2.87. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.

STIM's Quick ratio of 2.87 is fine compared to the rest of the industry. STIM outperforms 61.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.16
Quick Ratio	2.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.47% over the past year.

The Revenue has been growing slightly by 5.03% in the past year.

STIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.21% yearly.

EPS 1Y (TTM)8.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%12.12%

Revenue 1Y (TTM)5.03%

Revenue growth 3Y13.16%

Revenue growth 5Y6.21%

Sales Q2Q%3.61%

3.2 Future

STIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.41% yearly.

The Revenue is expected to grow by 16.19% on average over the next years. This is quite good.

EPS Next Y16.35%

EPS Next 2Y18.5%

EPS Next 3Y17.41%

EPS Next 5YN/A

Revenue Next Year9.92%

Revenue Next 2Y11%

Revenue Next 3Y12.12%

Revenue Next 5Y16.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STIM. In the last year negative earnings were reported.

Also next year STIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as STIM's earnings are expected to grow with 17.41% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y18.5%

EPS Next 3Y17.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for STIM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEURONETICS INC

NASDAQ:STIM (11/22/2024, 8:06:42 PM)

After market: 0.9292 +0.04 (+4.99%)

0.885

+0.05 (+5.94%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap26.86M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.14%
ROE	-388.26%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	75.7%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.98

Health

		Industry Rank	Sector Rank
Debt/Equity	4.9
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.16
Quick Ratio	2.87
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)8.47%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y16.35%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)5.03%

Revenue growth 3Y13.16%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NEURONETICS INC (STIM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens